Agilent Announces New Oligonucleotide Analysis Software for Biopharma Research
06 Junho 2022 - 9:00AM
Business Wire
Agilent Technologies Inc. (NYSE: A) today announced the release
of its MassHunter BioConfirm 12.0 software, which now supports data
generated by Agilent high-resolution LC/MS for oligonucleotide
purity analysis and sequence confirmation. MassHunter BioConfirm
12.0 will be on show at the 70th ASMS Conference on Mass
Spectrometry and Allied Topics being held June 5 - 9, 2022 in
Minneapolis, Minnesota.
Oligonucleotides are a class of molecules attracting increased
interest as therapeutics in the biopharma industry.
Oligonucleotides target gene expression through several mechanisms
and offer considerable promise for addressing a wide range of
diseases. However, challenges remain in developing
oligonucleotide-based biotherapeutics, including finding ways to
enhance their in vivo stability, more confidently and precisely
target their delivery, and quickly confirm sequences.
Agilent MassHunter BioConfirm 12.0 software introduces
enhancements to existing capabilities for protein analysis and adds
support for oligonucleotide analysis. The addition of
oligonucleotide support significantly extends the capabilities of
MassHunter BioConfirm, adding critical functionality for assessing
oligonucleotide purity and sequence confirmation – important
analytical steps in the use of oligonucleotides for biotherapeutics
and vaccine research and development.
"Customer requests for oligonucleotide analysis capabilities
have been steadily increasing. With MassHunter BioConfirm 12.0,
support for oligonucleotide analysis is available for the first
time,” said Sudharshana Seshadri, vice president and general
manager of Agilent’s Mass Spectrometry Division. “Agilent has a
strong commitment to expanding its biopharma solutions, especially
MS-based solutions. The addition of oligonucleotide support to
MassHunter BioConfirm aligns with Agilent’s continued focus on the
needs of our biopharma customers."
“I’m excited about the new oligonucleotide analysis package
Agilent has developed. Identification of impurities and sequencing
of oligonucleotides has previously been a slow and laborious
process,” said Leo Joyce, Ph.D., senior chemist III at Arrowhead
Pharmaceuticals. “The integrated BioConfirm 12.0 workflow is very
easy to use and generates accurate results quickly. This software
represents significant time and resource savings compared to the
traditional approach.”
The new MassHunter BioConfirm 12.0 workflows allow researchers
to identify full-length products and potential impurities. The
innovative MS/MS-based sequence confirmation enables confirmation
of oligonucleotide sequences in minutes instead of days or weeks of
manual interpretation. MassHunter BioConfirm 12.0 also has the
built-in flexibility for software customization to accommodate
specific oligo nomenclatures and continues to provide support to
ensure regulatory compliance and preservation of data
integrity.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a global leader in the
life sciences, diagnostics, and applied chemical markets,
delivering insight and innovation that advance the quality of life.
Agilent’s full range of solutions includes instruments, software,
services, and expertise that provide trusted answers to our
customers' most challenging questions. The company generated
revenue of $6.32 billion in fiscal 2021 and employs 17,000 people
worldwide. Information about Agilent is available at
www.agilent.com. To receive the latest Agilent news, please
subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn,
Twitter, and Facebook.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220606005419/en/
Media Contact Naomi Goumillout Agilent Technologies
+1.781.266.2819 naomi.goumillout@agilent.com
Agilent Technologies (NYSE:A)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Agilent Technologies (NYSE:A)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024